Young adult cancer survivors who had received their first rounds of cancer treatment between the ages of 20 and 44 were 1.5 times more likely to have more hospitalizations after remission than the general public.
Young adult cancer survivors who had received their first rounds of cancer treatment between the ages of 20 and 44 were 1.5 times more likely to have more hospitalizations after remission than the general public.
A new study published in the Journal of Clinical Oncology found that patients specifically with gastrointestinal cancer, leukemia, brain cancer, and lymphoma were twice as likely to be hospitalized at a greater rate, despite recent advances in cancer technology and treatment that have increased survival rates and life expectancy among young adults with cancer.
All patients with cancer, except for melanoma and testicular cancers, generally demonstrated significantly higher rates of hospitalization.
“Even when young adults survive cancer, the cancer still has an impact on their lives and their long-term health,” Nancy Baxter, colorectal surgeon at St. Michael’s Hospital and senior adjunct scientist at the Institute for Clinical Evaluative Sciences, said in a statement. “And this age group still has a lot of life to live.”
The authors noted that the findings mirrored a similar study that examined children diagnosed with cancer, which found that two-thirds of childhood cancer survivors developed long-term complications from cancer treatment, including chemotherapy, radiation, and surgery.
“The rate of hospitalization for 20-year survivors did not return to baseline, indicating a substantial and persistent burden of late effects among this generally young population,” the authors wrote.
Dr Baxter added that a better understanding of the late effects among the young adult cancer survivors may help to council the population on their future quality-of-life and may also steer them to options not closely linked with the long-term consequences demonstrated in the study.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma
March 7th 2024The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Read More